Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2011 13
2012 11
2013 13
2014 10
2015 7
2016 17
2017 10
2018 12
2019 7
2020 9
2021 5
2022 4
2023 4
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

113 results

Results by year

Filters applied: . Clear all
Page 1
Azilsartan medoxomil.
Al-Majed AA, Bakheit AHH, Al-Muhsin A, Al-Kahtani HM, Abdelhameed AS. Al-Majed AA, et al. Profiles Drug Subst Excip Relat Methodol. 2020;45:1-39. doi: 10.1016/bs.podrm.2019.10.001. Epub 2019 Dec 6. Profiles Drug Subst Excip Relat Methodol. 2020. PMID: 32164965 Review.
It acts by relaxing blood vessels to make it easier for blood to flow. Azilsartan Medoxomil's a comprehensive profile containing the description, formulae, Elemental Analysis, Uses and application. ...
It acts by relaxing blood vessels to make it easier for blood to flow. Azilsartan Medoxomil's a comprehensive profile containi …
Azilsartan medoxomil: a review of its use in hypertension.
Perry CM. Perry CM. Clin Drug Investig. 2012 Sep 1;32(9):621-39. doi: 10.2165/11209600-000000000-00000. Clin Drug Investig. 2012. PMID: 22877322 Review.
Over a longer treatment period of 24 weeks, azilsartan medoxomil showed sustained BP-lowering efficacy, with the reduction in 24-hour mean SBP at week 24 significantly greater with azilsartan medoxomil 40 or 80 mg once daily than with valsartan 320 mg …
Over a longer treatment period of 24 weeks, azilsartan medoxomil showed sustained BP-lowering efficacy, with the reduction in …
Azilsartan medoxomil: a new Angiotensin receptor blocker.
Zaiken K, Cheng JW. Zaiken K, et al. Clin Ther. 2011 Nov;33(11):1577-89. doi: 10.1016/j.clinthera.2011.10.007. Epub 2011 Nov 8. Clin Ther. 2011. PMID: 22071238 Review.
BACKGROUND: Azilsartan medoxomil is an angiotensin receptor blocker, approved on February 25, 2011 by the US Food and Drug Administration (FDA) for hypertension management. ...
BACKGROUND: Azilsartan medoxomil is an angiotensin receptor blocker, approved on February 25, 2011 by the US Food and Drug Adm …
Azilsartan medoxomil for the treatment of hypertension.
Vasiliou S. Vasiliou S. Drugs Today (Barc). 2011 Sep;47(9):647-51. doi: 10.1358/dot.2011.47.9.1688573. Drugs Today (Barc). 2011. PMID: 21971539 Review.
The use of angiotensin receptor blockers (ARBs) represents a favorable approach for the control of blood pressure in patients with hypertension. Azilsartan medoxomil, a prodrug that undergoes rapid hydrolysis to its active moiety azilsartan, is an angiotensin AT(1) …
The use of angiotensin receptor blockers (ARBs) represents a favorable approach for the control of blood pressure in patients with hypertens …
Azilsartan medoxomil: a new angiotensin II receptor antagonist for treatment of hypertension.
Baker WL, White WB. Baker WL, et al. Ann Pharmacother. 2011 Dec;45(12):1506-15. doi: 10.1345/aph.1Q468. Epub 2011 Nov 24. Ann Pharmacother. 2011. PMID: 22116996 Review.
Additional information shows added BP lowering when azilsartan medoxomil is combined with chlorthalidone. Adverse events are similar with azilsartan medoxomil versus other ARBs and include headache, dizziness, urinary tract infections, and fatigue. ... …
Additional information shows added BP lowering when azilsartan medoxomil is combined with chlorthalidone. Adverse events are s …
Exploring the Effectiveness and Safety of Azilsartan-Medoxomil/Chlorthalidone Versus Olmesartan-Medoxomil/Hydrochlorothiazide in Hypertensive Patients: A Meta-Analysis.
Kumar L, Khuwaja S, Kumar A, Memon UA, Kumar M, Ashok A, Lohana M, Qudoos A, Kashif M, Khatri M, Kumar S, Sapna F, Dass A, Varrassi G. Kumar L, et al. Cureus. 2023 Jun 30;15(6):e41198. doi: 10.7759/cureus.41198. eCollection 2023 Jun. Cureus. 2023. PMID: 37525792 Free PMC article. Review.
This study aims to assess the effectiveness and safety of azilsartan-medoxomil/chlorthalidone (AZI-M/CT) compared to olmesartan-medoxomil/hydrochlorothiazide (OLM/HCTZ) in patients with hypertension. ...
This study aims to assess the effectiveness and safety of azilsartan-medoxomil/chlorthalidone (AZI-M/CT) compared to olmesarta …
Azilsartan medoxomil in the treatment of hypertension: the definitive angiotensin receptor blocker?
Barrios V, Escobar C. Barrios V, et al. Expert Opin Pharmacother. 2013 Nov;14(16):2249-61. doi: 10.1517/14656566.2013.834887. Epub 2013 Sep 26. Expert Opin Pharmacother. 2013. PMID: 24070321 Review.
INTRODUCTION: Azilsartan medoxomil is the newest angiotensin receptor blocker marketed for the treatment of arterial hypertension. ...The MEDLINE and EMBASE search included both medical subject headings (MeSHs) and keywords including azilsartan or azilsartan …
INTRODUCTION: Azilsartan medoxomil is the newest angiotensin receptor blocker marketed for the treatment of arterial hypertens …
Efficacy of azilsartan medoxomil with chlorthalidone in hypertension.
Baker WL, Nigro SC, White WB. Baker WL, et al. Expert Rev Cardiovasc Ther. 2014 Jul;12(7):791-8. doi: 10.1586/14779072.2014.924853. Epub 2014 Jun 2. Expert Rev Cardiovasc Ther. 2014. PMID: 24881461 Review.
Azilsartan medoxomil (AZL) is the most recently approved angiotensin receptor blocker (ARB) for treating patients with hypertension. ...For this review, a literature search was conducted using MEDLINE and the keywords and MeSH terms azilsartan, azilsartan …
Azilsartan medoxomil (AZL) is the most recently approved angiotensin receptor blocker (ARB) for treating patients with hyperte …
113 results